Company’s 36-month beta value is 1.75.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
SKYE currently public float of 12.58M.The average trading volume of SKYE on April 17, 2024 was 30.20K shares.
SKYE) stock’s latest price update
Skye Bioscience Inc (NASDAQ: SKYE)’s stock price has gone rise by 25.00 in comparison to its previous close of 13.00, however, the company has experienced a 77.21% increase in its stock price over the last five trading days. InvestorPlace reported 2024-04-16 that Investors looking for a white-knuckle ride can easily find one by buying biotech stocks. There is a certain thrill in investing in a company making actual life-or-death decisions with drugs.
SKYE’s Market Performance
SKYE’s stock has risen by 77.21% in the past week, with a monthly rise of 23.01% and a quarterly rise of 508.61%. The volatility ratio for the week is 22.37% while the volatility levels for the last 30 days are 17.95% for Skye Bioscience Inc The simple moving average for the past 20 days is 28.12% for SKYE’s stock, with a 210.09% simple moving average for the past 200 days.
Analysts’ Opinion of SKYE
Many brokerage firms have already submitted their reports for SKYE stocks, with Oppenheimer repeating the rating for SKYE by listing it as a “Outperform.” The predicted price for SKYE in the upcoming period, according to Oppenheimer is $25 based on the research report published on April 12, 2024 of the current year 2024.
SKYE Trading at 49.17% from the 50-Day Moving Average
After a stumble in the market that brought SKYE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -16.28% of loss for the given period.
Volatility was left at 17.95%, however, over the last 30 days, the volatility rate increased by 22.37%, as shares surge +20.37% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +305.64% upper at present.
During the last 5 trading sessions, SKYE rose by +77.21%, which changed the moving average for the period of 200-days by +206.60% in comparison to the 20-day moving average, which settled at $12.82. In addition, Skye Bioscience Inc saw 497.43% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for SKYE
The total capital return value is set at -21.18.
Based on Skye Bioscience Inc (SKYE), the company’s capital structure generated 0.72 points at debt to capital in total, while cash flow to debt ratio is standing at -3.38. The debt to equity ratio resting at 2.61. The interest coverage ratio of the stock is -72.93.
Currently, EBITDA for the company is -12.09 million with net debt to EBITDA at 0.05. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.84.
Conclusion
In a nutshell, Skye Bioscience Inc (SKYE) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
